Company Overview
Max India Limited provides services related to senior living communities in India. It operates through four segments: Business Investments, Senior Living, Assisted Care, and Others. The company engages in treasury investments and property rental businesses. It also constructs, operates, and/or maintains senior living communities. In addition, the company caters to the seniors by providing care at home services and care homes facilities, as well as offers Antara AGEasy, a new-age holistic direct to consumer platform that helps seniors manage common chronic conditions. Further, it offers daily living/specialized care/memory care services for seniors; and management and consultancy and shared services. Additionally, the company engages in the learning and development activities; leasing of senior living communities; and management of investments activities. The company was formerly known as Advaita Allied Health Services Limited. Max India Limited was incorporated in 2019 and is based in Gurugram, India.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.24.
Recent Developments
- Mar 2026 Revenue of ₹190.56 Cr (+31.0% YoY); net profit ₹-121.85 Cr.
- Trailing 12 Months Year-on-year growth — revenue +31.0%.
- 5-Year Trend Long-term compounding — revenue CAGR -1.8%, profit CAGR -357.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -1.77% |
| 1 Year: | 30.98% |
Compounded Profit Growth
| 5 Years: | -357.85% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -27.04% |
| 6 Months: | +1.36% |
| 3 Months: | -5.27% |
| 1 Month: | -12.82% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)42.24 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -1.8% CAGR over 5 years.
- Earnings shrank at -357.9% CAGR over 5 years.
- Trading 32.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MAXIND Max India Limited NSEPHARMA | 150.66 | -6.32 | ₹791.31 Cr | 0.00% | -21.12% | -29.84% | -1.77% | -357.85% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,899.00 | 39.73 | ₹4.56 L Cr | 0.82% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 9,100.00 | 94.06 | ₹2.42 L Cr | 0.36% | 18.96% | 15.32% | 10.98% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,857.00 | 75.99 | ₹1.64 L Cr | 0.77% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 8,650.00 | 64.10 | ₹1.24 L Cr | 0.22% | 19.20% | 20.48% | 14.85% | 33.34% |
| 6 | LENSKART LENSKART SOLUTIONS LTD NIFTY_MIDNSEPHARMA | 684.90 | 236.17 | ₹1.19 L Cr | 0.00% | 7.21% | 5.65% | 35.38% | 66.99% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,120.00 | 22.36 | ₹1.13 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 8 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,385.00 | 28.85 | ₹1.12 L Cr | 0.88% | 14.86% | 11.27% | 7.23% | 11.45% |
| 9 | LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA | 1,840.00 | 111.85 | ₹99,333.61 Cr | 0.13% | 19.53% | 16.77% | 3.77% | 4.00% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 56.00 Cr | 41.00 Cr | 49.00 Cr | 41.00 Cr | 45.00 Cr | 26.00 Cr | 43.00 Cr | - | 41.52 Cr | 36.67 Cr | 45.16 Cr | 43.10 Cr | 65.63 Cr |
| Cost of Revenue | - | - | - | - | - | - | - | - | 13.81 Cr | 8.75 Cr | 14.42 Cr | 12.83 Cr | 16.73 Cr |
| Gross Profit | - | - | - | - | - | - | - | - | 27.71 Cr | 27.92 Cr | 30.74 Cr | 30.27 Cr | 48.90 Cr |
| Operating Expenses | 55.00 Cr | 53.00 Cr | 54.00 Cr | 58.00 Cr | 66.00 Cr | 54.00 Cr | 64.00 Cr | - | 72.41 Cr | 61.54 Cr | 66.94 Cr | 66.56 Cr | 69.42 Cr |
| Operating Income | -1.00 Cr | -14.00 Cr | -7.00 Cr | -19.00 Cr | -24.00 Cr | -32.00 Cr | -26.00 Cr | - | -44.70 Cr | -33.62 Cr | -36.20 Cr | -36.29 Cr | -20.52 Cr |
| EBITDA | 1.00 Cr | -12.00 Cr | -5.00 Cr | -17.00 Cr | -21.00 Cr | -28.00 Cr | -21.00 Cr | - | -37.22 Cr | -15.37 Cr | -26.03 Cr | -31.88 Cr | -8.80 Cr |
| Interest Expense | 2.00 Cr | 1.00 Cr | 1.00 Cr | 1.00 Cr | 1.00 Cr | 1.00 Cr | 2.00 Cr | - | 2.83 Cr | 3.52 Cr | 4.06 Cr | 3.45 Cr | 2.76 Cr |
| Pretax Income | 1.00 Cr | -10.00 Cr | -2.00 Cr | -17.00 Cr | -20.00 Cr | -27.00 Cr | -22.00 Cr | - | -45.30 Cr | -24.66 Cr | -36.03 Cr | -41.42 Cr | -18.86 Cr |
| Tax Provision | 3.88 Cr | -1.90 Cr | -3.20 Cr | -1.36 Cr | -1.20 Cr | -0 | -66.00 L | - | 79.00 L | 98.00 L | -1.96 Cr | 1.43 Cr | 43.00 L |
| Net Income | -4.00 Cr | -12.00 Cr | -5.00 Cr | -18.00 Cr | -22.00 Cr | -27.00 Cr | -23.00 Cr | - | -46.09 Cr | -25.64 Cr | -34.07 Cr | -42.85 Cr | -19.29 Cr |
| Diluted EPS | -0.82 | -2.38 | -0.91 | -3.48 | -4.20 | -5.25 | -4.42 | - | -10.36 | -5.44 | -6.52 | -8.17 | -3.67 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | 213.00 Cr | 128.00 Cr | - | 201.03 Cr | 175.63 Cr | 145.49 Cr | 190.56 Cr |
| Cost of Revenue | - | - | - | 91.42 Cr | 63.53 Cr | 32.72 Cr | 52.73 Cr |
| Gross Profit | - | - | - | 109.61 Cr | 112.10 Cr | 112.77 Cr | 137.83 Cr |
| Operating Expenses | 266.00 Cr | 150.00 Cr | - | 109.26 Cr | 173.54 Cr | 249.77 Cr | 268.79 Cr |
| Operating Income | -61.00 Cr | -32.00 Cr | - | 35.31 L | -61.45 Cr | -137.00 Cr | -130.96 Cr |
| EBITDA | -53.00 Cr | -22.00 Cr | - | 11.65 Cr | -34.32 Cr | -111.50 Cr | -82.08 Cr |
| Interest Expense | 27.00 Cr | 24.00 Cr | - | 6.21 Cr | 4.56 Cr | 8.06 Cr | 13.79 Cr |
| Pretax Income | 237.00 Cr | -64.00 Cr | - | -3.01 Cr | -49.03 Cr | -138.38 Cr | -120.97 Cr |
| Tax Provision | 4.74 Cr | 10.88 Cr | - | 7.37 Cr | 7.34 Cr | 1.31 Cr | 88.00 L |
| Net Income | 232.00 Cr | -53.00 Cr | - | -10.38 Cr | -56.38 Cr | -140.39 Cr | -121.85 Cr |
| Diluted EPS | 29,706.00 | -8.30 | - | -2.06 | -12.36 | -31.55 | -23.85 |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Total Assets | 1,024.00 Cr | 996.00 Cr | - | 753.40 Cr | 684.34 Cr | 632.85 Cr | 669.25 Cr |
| Current Assets | - | - | - | 459.13 Cr | 343.25 Cr | 260.52 Cr | 380.56 Cr |
| Cash & Equivalents | - | - | - | 88.73 Cr | 116.03 Cr | 22.70 Cr | 26.58 Cr |
| Inventory | - | - | - | 51.01 Cr | 6.13 Cr | 16.64 Cr | 15.52 Cr |
| Receivables | - | - | - | 2.86 Cr | 4.94 Cr | 22.20 Cr | 37.10 Cr |
| Total Liabilities | - | - | - | 211.29 Cr | 192.00 Cr | 274.16 Cr | 260.95 Cr |
| Current Liabilities | - | - | - | 161.44 Cr | 138.84 Cr | 165.25 Cr | 161.71 Cr |
| Long Term Debt | - | - | - | 22.34 Cr | 81.89 L | 93.82 L | 1.09 Cr |
| Total Debt | 182.00 Cr | 145.00 Cr | - | 45.30 Cr | 43.57 Cr | 102.30 Cr | 96.20 Cr |
| Total Equity | 706.00 Cr | 653.00 Cr | - | 542.11 Cr | 492.34 Cr | 358.69 Cr | 408.30 Cr |
| Shares Outstanding | - | - | - | 4.56 Cr | 4.57 Cr | 4.61 Cr | 5.25 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -19.00 Cr | 73.00 Cr | - | 69.42 Cr | -102.34 Cr | -127.60 Cr | -94.72 Cr |
| Investing Cash Flow | -526.00 Cr | 13.00 Cr | - | 124.07 Cr | 158.64 Cr | 46.82 Cr | -49.72 Cr |
| Financing Cash Flow | 557.00 Cr | -73.00 Cr | - | -118.54 Cr | -29.00 Cr | -12.55 Cr | 148.32 Cr |
| Capital Expenditure | -190.00 Cr | -12.00 Cr | - | -3.66 Cr | -28.75 Cr | -35.88 Cr | -51.33 Cr |
| Free Cash Flow | -209.00 Cr | 61.00 Cr | - | 65.75 Cr | -131.10 Cr | -163.48 Cr | -146.05 Cr |
| Net Change in Cash | 12.00 Cr | 12.00 Cr | - | 74.94 Cr | 27.30 Cr | -93.33 Cr | 3.88 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | 54.5% | 63.8% | 77.5% | 72.3% |
| Operating Margin % | -28.6% | -25.0% | - | 0.2% | -35.0% | -94.2% | -68.7% |
| Net Margin % | 108.9% | -41.4% | - | -5.2% | -32.1% | -96.5% | -63.9% |
| ROE % | 32.9% | -8.1% | - | -1.9% | -11.5% | -39.1% | -29.8% |
| ROCE % | - | - | - | 0.1% | -11.3% | -29.3% | -25.8% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MAXIND
Ranking Member Maxine Waters Seeks Answers from SEC on Foreign Stock Manipulation Schemes Targeting American Investors - U.S. House Committee on Financial Services Democrats (.gov)
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxQTXhuYkVXUzJJMnVsbEtqLVE0RTV3NzZ4RkxpOE5DZzJ2ZE5TX3RDR1UyVXRfbTZFZG00aE9KSTU1X2d5VHRJOW0ybmpWY3d4RXBrVzNIMGxDLU5yemRuajdpYU1pT1JvUHdzcmsyaWRDLTVQZDBIbV9KSE1mcnFHX1VTT3FoakdJYVFsX1…
Maxine Patricia Stock - legacy.com
<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxPVjViUWVGT1N1UXJXTUtGSXEydkNkZ0tYaEhOdndvRXZyajNyRlhYZVVIRklyT1d5TzFTWEhSQVZ3YzM5WTF5cHBCTllzei12emNFQzJyZXI3R2JLb0pvUDUycEY5dExLN1llVlZOVXNlU0c1V0hzUVFQNmZ6ekt5Yw?oc=5" target="_…
Here's Why We're Watching Max India's (NSE:MAXIND) Cash Burn Situation - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxPVUtiSk5IY2dBUGZWbldRVWdlcGVKbGJXNndpVjdoR0d6UkZxLTZBS1AySGlMZ1R6UVhIYm4wMnNSREhUT0hjV3FTVmNBZk1zaG5HSC1TSlFDMXVkZjZiRG55cm0zaUxpV0I0aXE4d3h5ckZScFpyYkJIR3RoNEkzTkc1c1dNMS1PRmx4VG…
Max India (MAXIND.NS) Q2 2026 Earnings: Revenue Surges 31% YoY but Bottom Line Remains Under Pressure - vinanet.vn
<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxNeDFPNi1sXzlLdzVxcTRNUVcyUGttbXNYZUFEcGtRVVdPbmpxQVEzZ0h3OHhHYWp6andiVU1vODlxRG1wd1QxSzg4UGdfazNhck1KbmVCUzM0cU5lYkk2YWtPbUMyejlQOVFRTE5QZUxJZ3FwNHNDNzdBall1YUUzSHEtOFoxaW9hdUVWRE…
Max India Limited's (NSE:MAXIND) Business Is Trailing The Industry But Its Shares Aren't - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxNN2hlam13N2VRRWV0Ykk0NXh3ZlJ5dlNObk9jSlh3VGYwNjYzYy1hMExwM0o4UktHc25LMWdra0NQdXVDR0hUSTBudHoydFA0N1hpdmNhTjF5bHdiS3VhMDZnd2p6SlNfRzhiYU5fSUM2emZ6aGJqa2dEWFBMeGlhVWF5MnZhaXZMX0U5bT…
Max India (MAXIND.NS) Gains 2.32%, Nears Key Resistance at ₹165.62 - Stock Surge Alerts - siam.in
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxOTVFaNlYzUXJBREhSdWdCckRabVVvUmcwRVlZUnRRd01Qejhjdkp0M1RZRG9CTHA0RTdqNmQ5OUVqSUY2NmpXbUlNWnp1VEpEQnlLZ2EzdXZUaEV3YW5pWElxQlFSN2RUNWVRUHhsbHZmb1NvS0xyQlRfY0xCNld2eW5hSXZBeFR1WERILV…
MAXIND — Frequently Asked Questions
What is the current share price of Max India Limited (MAXIND)?
As of 2026-09-08 04:53 IST, Max India Limited (MAXIND) trades at ₹150.66 on NSE. Its 52-week range is ₹122.85 to ₹224.11.
What is the market capitalisation of MAXIND?
Max India Limited (MAXIND) has a market capitalisation of ₹791.31 Cr on NSE.
What is the P/E ratio of MAXIND?
MAXIND trades at a trailing price-to-earnings (P/E) ratio of -6.32. The industry average P/E is 41.64. Its price-to-book (P/B) ratio is 2.20.
What is the return on equity (ROE) of MAXIND?
MAXIND has a return on equity (ROE) of -29.84%. Its return on capital employed (ROCE) is -21.12%.
Is MAXIND a good stock to buy?
This page provides a data-driven analysis of Max India Limited (MAXIND), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.